This is not the most recent version of the article. View current version (1 SEP 2016)

Intervention Protocol

You have free access to this content

Vilanterol and fluticasone for asthma

  1. Colin Powell1,*,
  2. Kerry Dwan2,
  3. Stephen J Milan3,
  4. Nicola Walters4,
  5. Lynne Bax5

Editorial Group: Cochrane Airways Group

Published Online: 7 OCT 2013

DOI: 10.1002/14651858.CD010758

How to Cite

Powell C, Dwan K, Milan SJ, Walters N, Bax L. Vilanterol and fluticasone for asthma (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD010758. DOI: 10.1002/14651858.CD010758.

Author Information

  1. 1

    Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Department of Child Health, Cardiff, UK

  2. 2

    University of Liverpool, Department of Biostatistics, Liverpool, England, UK

  3. 3

    St George's University of London, Population Health Sciences and Education, London, UK

  4. 4

    St George's NHS Healthcare Trust, Chest Unit, London, UK

  5. 5

    Lancashire Care NHS Foundation Trust, Preston, UK

*Colin Powell, Department of Child Health, Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, UK.

Publication History

  1. Publication Status: New
  2. Published Online: 7 OCT 2013


This is not the most recent version of the article. View current version (01 SEP 2016)


Additional references

Barnes 1998
Bisgaard 2006
Bleecker 2011
  • Bleecker ER, Bateman ED, Busse WW, Lotvall J, Woodcock A, Frith L, et al. Consistently favorable safety profile of Fluticasone Furoate (FF), A Once-Daily (OD) inhaled corticosteroid (ICS), across a range of treatment steps in patients with uncontrolled asthma. American Thoracic Society Conference; 2011 May 15; Denver. 2011.
Braman 2006
  • British Guideline on the Management of Asthma. A national clinical guideline.‎ (accessed 10/12/2012).
Cazzola 2011
CDC 2012
  • Centers for Disease Control and Prevention. Vital signs. (accessed 10/12/2012).
CDCP 2011
  • Centers for Disease Control and Prevention. Trends in Asthma Prevalence, Health Care, and Mortality in the United States, 2001-2010. CDC (accessed 10/12/2012).
Clayton 2005
  • Clayton S. Paediatric asthma: overcoming barriers to an improved quality of life. British Journal of Nursing 2005; Vol. 14, issue 2:80–5.
Eid 2010
  • Eid NS, Noonan MJ, Chipps B, Parasuraman B, Miller C, O’Brien CD. Once –vs twice-daily budesonide/formoterol in 6- to 15-year old patients with stable asthma. Pediatrics 2010;126(3):e565-e575.
Fuso 2013
GINA 2011
  • Global Initiative for Asthma (GINA). GINA Report, Global Strategy for Asthma Management and Prevention. Updated December 2011. (accessed 10/12/2012).
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration. Available from, 2011.
Kempsford 2013
  • Kempsford R, Norris V, Siederer S . Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulmonary Pharmacology and Therapeutics 2013;26(2):256-64.
Krishnan 2006
  • Krishnan V, Diette GB, Rand CS, Bilderback AL, Merriman B, Hansel NN, et al. Mortality in patients hospitalized for asthma exacerbations in the United States. American Journal of Respiratory and Critical Care Medicine 2006;174(6):633-8.
Lotvall 2012
  • Lotvall J, Bateman ED, Bleecker ER, Busse WW, Woodcock A, Followse R, et al. 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids. European Respiratory Journal 2012;40(3):570–9.
Montuschi 2008
Montuschi 2010
Montuschi 2011
Mortaz 2008
  • Mortaz E, Rad MV, Johnson M, Raats D, Nijkamp FP, Folkerts G. Salmeterol with fluticasone enhances the suppression of IL-8 release and increases the translocation of glucocorticoid receptor by human neutrophils stimulated with cigarette smoke. Journal of Molecular Medicine 2008;86:1045–56.
NHS 2011
  • NHS 2011 HES online hospital episode statistics. (accessed 10/12/2012).
NIH 2007
  • Guidelines for the Diagnosis and Management of Asthma (EPR 3). 2007 (accessed 10/12/2012).
Nocker 1996
  • Nocker RE Schoonbrood DF, van de Graaf EA, Hack CE, Lutter R, Jansen HM, et al. Interleukin-8 in airway inflammation in patients with asthma and chronic obstructive pulmonary disease. International Archives of Allergy and Immunology 1996;109(2):183-91.
Ordonez 1998
Patel 2008
Powell 2003
Remington 2005
  • Remington TL, DiGiovine B. Long-acting beta 2-agonists: anti-inflammatory properties and synergy with corticosteroids in asthma. Current Opinion in Pulmonary Medicine 2005;11:74-8.
Review Manager 2012 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Usmani 2005
  • Usmani OS, Ito K, Maneechotesuwan K, Ito M, Johnson M, Barnes PJ, et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Amercian Journal of Respiratory and Critical Care Medicine 2005;172(6):704-12.
Weiner 1995
WHO 2007
  • Bousquet J, Khaltaev N (editors). Vital signs. World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. WHO Press Geneva Centers for Disease Control and Prevention. (accessed September 2013).
WHO 2011
  • World Health Organization. Health topics: asthma. (accessed 13 September 2011).
Woodcock 2011
  • Woodcock A, Bateman ED, Busse WW, Lötvall J, Snowise NG, Forth R, et al. Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo controlled trial. Respiratory Research 2011;12(1):132.
Wu 2007